Lurbinectedin–Atezolizumab Maintenance Receives FDA Approval in Small Cell Lung Cancer
In this article
2 October 2025: the FDA approved lurbinectedin (Zepzelca®, Jazz Pharmaceuticals) + atezolizumab (Tecentriq®) or Tecentriq Hybreza® (SC) in combination for patients with extensive-stage small cell lung cancer (ES-SCLC) following first-line induction (atezolizumab ± Hybreza + carboplatin + etoposide) , for maintenance treatment . This decision marks a new standard for adults whose disease has not progressed after induction, with the potential to prolong survival and disease control .
What Is Lurbinectedin, and How Does It Work?
Lurbinectedin (Zepzelca®)is a chemotherapy drug developed from a marine-derived compound that binds to DNA to stop cancer cells from growing and proliferating.
- Binds to specific grooves in DNA and suppresses oncogenic transcription.
- Degrades RNA Polymerase II to stop the copying of genetic information.
- Double-strand breaks and apoptosis are triggered.
🌊 Lurbinectedin’s Story from the Sea
- 1980s: Scientists discovered, in a sea squirt (Ecteinascidia turbinata), a potent anticancer compound called ET-743.
- 1990s: This compound was developed as trabectedin (Yondelis®) .
- 2000s: Trabectedin received clinical approval for soft tissue sarcomas and ovarian cancer.
- 2010s: A more potent and selective derivative, lurbinectedin (PM1183) , was synthesized.
- 2020: The FDA granted accelerated approval for platinum-resistant small cell lung cancer.
Today, lurbinectedin can now be used in combination with immunotherapy for maintenance treatment .
🔎 A Numerical Summary of the IMforte Trial (OS & PFS)
The lurbinectedin + atezolizumab combination extends median overall survival by 2.6 months (13.2 vs 10.6 months) and extends time to progression by 3.3 months (5.4 vs 2.1 months). This means a reduction in mortality risk of 27% and a 46% reduction in progression risk .
🎯 Role in Clinical Practice
- Adults receiving first-line carboplatin + etoposide + atezolizumab (IV or Hybreza SC) who have a response or stable disease and no progression of ES-SCLC.
- Maintenance treatment begins as soon as induction is complete and continues until progression/unacceptable toxicity .
💉 Dose and Administration
| Drug | Schedule |
|---|---|
| Lurbinectedin | 3.2 mg/m² IV q21g (every twenty-one days) (until progression/toxicity) |
| Atezolizumab (IV) | 840 mg q2w or 1200 mg q3w or 1680 mg q4w |
| Tecentriq Hybreza (SC) | 1875 mg atezolizumab + 30,000 U hyaluronidase, q3w |
Note: The formulation and interval can be individualized according to patient preference, access, infusion capacity and toxicity.
⚠️ Safety Considerations
- Lurbinectedin: Myelosuppression, hepatotoxicity, extravasation → tissue necrosis, rhabdomyolysis, embryo-fetal toxicity.
- Atezolizumab/Hybreza: Severe immune-mediated reactions (pneumonitis, hepatitis, etc.), infusion/administration reactions, complications of allogeneic HSCT, embryo-fetal toxicity.
🌍 Project Orbis: Concurrent Review
Approval was conducted within the FDA OCE’s Project Orbis framework, in collaboration with authorities in Australia, Canada, Israel and Switzerland; applications are also progressing at these agencies.
🧭 Practical Clinical Tips
- Patient selection: Patients with ECOG 0–1, a good response/stability after induction and adequate hematologic reserve are ideal candidates.
- Monitoring: During the first 2–3 cycles, hematologic toxicity requires close CBC/liver-function monitoring; if necessary, use dose delays/reductions.
- Formulation selection: Hybreza (SC) may reduce pressure on centers; IV intervals (q2–4w) can be adjusted according to patient/hospital logistics.
🔗 Sources
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.